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BACKGROUND: Type 2 Diabetes Mellitus (DM) is one of dominant factors in cardiovascular deaths and induces endothelial dysfunction. A definite sign 
of endothelial dysfunction is foam cells formation derived 
from oxidized LDL. This study was conducted to determine 
the effect of Polysaccharides Peptides (PsP) Ganoderma 
lucidum to foam cell counts and lipid profile in diabetic 
model rats with high-fat diet. 
METHODS: Treatment group was categorized to negative 
control, positive control, DM-50, DM-150, and DM-300. 
Type 2 DM induced by Streptozotocin. PsP was administered 
with predetermined doses on each treatment’s group (50, 
150 and 300 mg/kgBW) for 12 weeks. Measurements of 
foam cell count were held after obtaining rat’s aorta. To 
assess lipid profile, blood sample was taken from the rat's 
heart. The data were analyzed by One-way ANOVA and 
Post Hoc Tukey tests.
RESULTS: The administration of Ganoderma lucidum PsP 
to diabetic model rats provided a significant difference in 
lowering foam cell (p=0.017; CI 95%). It also gave significant 
difference between levels of each lipid components (Total 
Cholesterol, Trygliceride, LDL and HDL) in at least two 
treatment groups (p=0.010; CI 95%). Based on Post Hoc 
Tukey tests, the relationship between administration of PsP 
and foam cell is significant (p=0.002).
CONCLUSION: PsP has antioxidant and anti-inflammatory 
effect in type 2 DM model Rattus norvegicus strain Wistar, 
which can inhibit atherosclerosis and endothelial damage 
process. Further studies are necessary to evaluate the 
benefits of PsP as an adjuvant therapy in the management of 
diabetic dyslipidemia.
KEYWORDS: PsP, Ganoderma lucidum, foam cell, lipid 
profile, DM
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Abstract
Introduction
By 2013, a total of 382 million people in the world suffer 
from diabetes mellitus (DM). In the year 2035, this figure 
will be increased to 592 million. Indonesia is included in 10 
countries in the world with the largest number of diabetics, 
with the number of patients as much as 8.5 million by 
2013 (7th rank) and is expected to be increased to 14.1 
million of patients by 2035 (6th rank).(1) Atherosclerosis is 
2-6 times more  likely  in  type  1  and  type 2 DM than 
nondiabetic patients.(2) Cardiovascular disease is the 
leading complication caused death and disability in patients 
with diabetes.(1) Major cardiovascular event is the global 
number one cause of death. It is estimated about 17.3 million 
people were died from cardiovascular diseases in 2008, 
representing 30% of all deaths globally.(3) This is primarily 
caused by atherosclerosis, i.e., the plaque accumulates 
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Methods
in the arteries that are supposed to bring oxygen-rich 
blood to the entire body.(4) The formation of plaque and 
endothelial damage begins first with the formation of foam 
cell originating from the macrophage phagocytosis which 
acts against the accumulation of lipid in endothelial cells so 
that it can act as an indicator of the occurrence of vascular 
damage due to DM.(5) 
 Patients with DM  have a number of factors that 
increase atherosclerosis risk. Change in plasma lipid levels 
associated  with diabetes  is  one  of  the key factors.(6) 
Dyslipidemia, which affects nearly 50% of patients with 
type 2 DM, is one of the cardiovascular risk factors, 
characterized by increased levels of triglycerides, low 
high density lipoprotein (HDL) levels, and the number of 
particles of small dense low density lipoprotein (LDL).
(7) The control of dyslipidemia is needed to prevent the 
risk of complications of DM. One of routine examination 
that can be done to detect the presence of dyslipidemia is 
by obtaining lipid profile test. The adenosin tryphosphat 
(ATP) III  guidelines  recommend  that  every individual is 
expected to perform screening with lipid profile test begins 
from the age of 21 years old, once every 5 years and in 
shorter  intervals  if  they  have  a  certain  disease  or  risk 
factor.(8)
 In diabetic patients, oxidative stress increases and 
can accelerate the development of complications through 
the metabolism of glucose and free fatty acid accumulation 
on the state of diabetes and insulin resistance.(9) The 
condition of oxidative stress is increased in DM patients, 
requiring sources of antioxidants in order to compensate. 
One of the sources  of  antioxidants  are  obtained  in  the 
polysaccharides peptide (PsP). PsP is one of the compounds 
which can be obtained from the extract of Ganoderma 
lucidum fungus.(10) 
 Some studies mention that the extract of Ganoderma 
lucidum PsP has an effect as anti-hyperglycemia, anti-
inflammatory and anti-tumor. Ganoderma lucidum PsP 
containing the antioxidative enzymes and are capable 
of suppressing reactive oxygen species (ROS) so that it 
becomes more stable. Antioxidant effects of Ganoderma 
lucidum PsP can be used to prevent and treat atherosclerosis 
and type 2 DM.(10,11)
Brawijaya for 1 week. The whole rats were given standard 
feed in order to adapt the rats with its environment. The 
feed was given once in 24 hours, which later replaced by the 
next day. Each feed was weighed 30 grams. After a period 
of acclimatization of rats, it continued with the process of 
randomization of the rats to be grouped into each treatment’s 
group. 
 The treatment in each group was begun by categorizing 
the rats to negative control group, positive control group, 
DM-50 group, DM-150 group, and DM-300 group. The 
given feed on each group treatment was a high-fat diet (HFD) 
or atherogenic diet that was made with the composition of 
chicken feed (ParS 57.3% and flour 31.8%) and added with 
1.9% cholesterol, 0.1% cholic acid and 8.9% pork oil. HFD 
was given every day with a 24-hours gap with the weight 
of each feed 40 grams over the past 4 weeks. Then the rats 
were induced with Streptozotocin (STZ) 30 mg/kgBW so 
that it could be categorized as a type 2 DM. Blood glucose 
tests were also carried out in rats after administration of STZ 
to determine whether random blood sugar levels of the rat 
was already included in type 2 DM criteria or not. After that, 
the PsP was given in conjunction with the HFD for 4 weeks 
and ended with surgery. HFD was administered with a total 
allotment of time i.e., 12 weeks to ensure the occurrence 
of endothelial dysfunction that may be observed with the 
histopathology specimen in diabetic model rats.  
 PsP was administered with predetermined doses on 
each treatment’s group (50 mg/kgBW, 150 mg/kgBW and 
300 mg/kgBW). Determination of Ganoderma lucidum PsP 
doses of 50, 150, and 300 mg/kgBW was done based on 
previous studies regarding the effect of Ganoderma lucidum 
administration to diabetic model rats.(11,12)
 The measurement of foam cell count was held after 
the surgery of the rats, and obtaining the aorta of the rats in 
order to assess the foam cell count. Tissue fixation was done 
by using paraffin block method which was then mounted on 
the glass objects (slides) for observing the foam cells. Aortic 
preparations using to observe the foam cell were stained 
with Hematoxylin-Eosin. After that, the foam cell was read 
by using light microscope with a magnification of 400x and 
used software Dot Slide Olyvia with field of view 10 times 
for each aortic preparation.(13)
 To assess lipid profile, the preparation was begun 
with surgery. A blood sample was taken from the rat's heart 
followed by separation of blood serum from blood cells. 
Lipid profile measurement was done by using analyzer 
machine, the Cobas Mira. Data analysis was done by using 
One-way ANOVA and Post Hoc Tukey tests.
This research used 35 Wistar rats (Rattus norvegicus) in a 
central laboratory of life sciences Bioscience University of 
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Results
Figure 1. Mean of foam cell count of 
each treatment group.
The Effect of PsP on Foam Cell Count
The administration of PsP decreased foam cell count 
observed in the aortic tissue of diabetic model rats, which 
was observed through aortic tissue of diabetic model rats. 
Compared to positive and negative control groups, the 
diabetic model rats group which were given certain dose of 
PsP showed decrease of mean foam cell count. In positive 
control group (DM), the mean of foam cell count was 
obtained as the highest level among all treatment groups, 
i.e., about 4.375±1.797 cells per 10 field of view. The high-
fat diet group with PsP dose 150 mg/kgBW showed foam 
cell count about 1.875±0.854 cells per 10 field of view, more 
less compared to DM+PsP 50 group which showed foam cell 
count as 3.167±1.607 cells per 10 field of view. DM+PsP 
300 group showed the least foam cell count compared to all 
treatment groups, i.e., as many as 1.750±0.957 cells per 10 
field of view (Figure 1).
 The administration of Ganoderma lucidum PsP 
provided a significant difference in lowering the number of 
foam cell (p=0.017) because the value of p for foam cells was 
smaller than 0.05. The Post Hoc Test with Tukey HSD method 
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showed that the results of the significance of a decrease in 
the foam cell count with a specific dose of PsP Ganoderma 
lucidum with doses of 50, 150 and 300 mg/kgBW in Wistar 
rats (Rattus norvegicus) were different within each group. 
There was a significant difference between the negative 
control group, DM+PsP 300, DM+PsP150, and MD+PsP50 
compared to the positive control group (Figure 2). It can 
be assumed that the administration of PsP may cause a 
significant difference in foam cell counts as compared to the 
positive control group. The administration of PsP gave no 
significant difference compared to negative control group. 
The relationship between the administration of the PsP and 
foam cell was significant (p=0.002; r=-0.731). 
 The correlation between the groups that received the 
HFD and Ganoderma lucidum PsP dose showed a decrease 
in the number of foam cell approaching the amount of the 
foam cell count in standard diet group. DM+PsP150 group 
and DM+PsP300 group were the groups that demonstrate 
the non-significant p value (approaching 1.00) and very 
powerful r (0.993 and 1.000) as compared to negative control 
group. This showed that the effects of the administration of 
Ganoderma lucidum PsP had already occurred on the dose 
of 150 mg/kgBW which proved by the p value that was 
not significant and the r value that was very powerful. The 
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Figure 2. Foam cell in negative control group (A), positive control group (B), DM+PsP 50 group (C), DM+PsP 150 group (D) and 
DM+PsP 300 group (E).
The administration of a diet high in cholesterol and 
saturated fat continuously led to disruption of either lipid 
or carbohydrate metabolism. Impaired fat metabolism will 
cause an increase in LDL and decrease in HDL that will 
become the source of dyslipidemia and eventually fall on 
the condition of type 2 DM in which occurs the process of 
atherosclerosis with chronic inflammation that causes the 
development of endothelial dysfunction.(14) HFD which 
is given to the rats in positive control group (DM) is a 
A B C
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conclusion that can be drawn was a dose of 150 mg/kgBW 
of Ganoderma lucidum PsP was an adequate dose for acting 
as an external antioxidant in type 2 DM, compared to the 
dose of 300 mg/kgBW. Another consideration which led to 
an adequate dose of PsP 150 mg/kgBW was a dose of 150 
mg/kgBW PsP more easily consumed as well as the fewer 
side effects and lower manufacturing price. 
 Compared to the group received the highest dose 
of PsP, i.e., 300 mg/kgBW PsP, the foam cell count of 
the negative control group remained less than a group of 
DM-PsP 300 group. This is because a group of PsP 300 is 
receiving HFD that was not given to negative control group, 
instead.  
The Effect PsP on Lipid Profile
Total cholesterol levels measurement results showed that 
the lowest mean level was obtained in the negative control 
group (47.20 mg/dL) and the highest mean level was in the 
positive control group (130.65 mg/dL). The diabetic group 
with PsP 50 had an average of 115.75 mg/dL, diabetic group 
with PsP 150 of 103.05 mg/dL and diabetic group with PsP 
300 of 89.50 mg/dL (Figure 3A). 
 The results of the measurement of triglyceride levels 
showed that the lowest average was obtained in the negative 
control group (76.20 mg/dL) and the highest mean level was 
in the positive control group (661.60 mg/dL). The diabetic 
group with PsP 50 had an average of 537.60 mg/dL, diabetic 
group with PsP 150 of 347.80 mg/dl and diabetic group with 
PsP 300 of 274.80 mg/dL (Figure 3B).  
 Figure 3C showed the result of the measurement of 
LDL levels. The calculation of the lowest mean level was 
obtained in the negative control group (13.16 mg/dL) and 
the highest mean level was in the positive control group 
(41.08 mg/dL). The diabetic group with PsP 50 had an 
average of 25.30 mg/dL, diabetic group with PsP 150 of 
24.56 mg/dL and diabetic group with PsP 300 of 24.58 mg/
dL. A decrease in LDL cholesterol levels seems in line with 
the increased dose of PsP. 
 The results of measurements of the levels of HDL 
(Figure 3D) showed that the lowest mean level was obtained 
in the positive control group (22.92 mg/dL) and the highest 
mean level in the negative control group (33.30 mg/dL). 
The diabetic group with PsP 50 had an average of 24.63 
mg/dL, diabetic group with PsP 150 of 30.54 mg/dL and 
diabetic group with PsP 300 of 31.08 mg/dL. 
 Using One-way ANOVA test with 95% confidence 
interval, there was a significant difference between the levels 
of each lipid components in at least two treatment groups 
(p=0.010). Total cholesterol levels in positive control group 
were significantly different compared to diabetic group with 
PsP 300. This showed that the dose of 300 mg/kgBW could 
significantly lower total cholesterol levels in diabetic model 
rats. In addition, administration of PsP 300 mg/kgBW could 
also lower the level of triglycerides (p=0.001). Administered 
a dose of 150 mg/kgBW PsP could lower the level of LDL 
cholesterol (p=0.010) significantly, but gave no significant 
differences in the levels of HDL cholesterol (p=0.232).
Discussion
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Figure 3. Graphic of mean level of lipid profile in each treatment group: total cholesterol level (A), triglyceride (B), LDL cholesterol 
(C)  and  HDL cholesterol (D).
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feed containing high concentration of unsaturated fats or 
polyunsaturated fatty acids (PUFA) so is very potential in 
increasing the level of oxidative stress in the animal body. 
PUFAs are the type of fat that is susceptible to a variety of 
oxidative processes that occur in the body. One of the most 
influential forms of free radicals that cause an increase in 
oxidative stress in type 2 DM condition is hydrogen peroxide 
(H2O2). Lipid peroxidation, i.e., damage of PUFA because 
of the activity of free radicals in changing the fatty chain 
form of PUFA, also caused by H2O2 and induce cell damage 
which is characterized by damage of the cell membrane, 
enzyme inactivation, and the production of secondary toxic 
products which harm the cells.(15) 
 In this study, there are not significantly different results 
between the negative control group and the HFD group that 
received Ganoderma lucidum PsP at largest dose , i.e., 300 
mg/kgBW. The HFD group with 300 mg/kgBW PsP has 
foam cell number differed more or less one cell compared to 
the mean amount of foam cell in the negative control group. 
This can occur because of Ganoderma lucidum PsP have 
properties as an external antioxidant on the conditions of 
type 2 DM. In the former study, Ganoderma lucidum has 
been obtained useful in lowering plasma blood glucose, 
PEPCK gene expression, and body weight of rat as the 
subject (the reduction of body fat, particularly abdominal 
fat) as a benefit of the PsP as a therapy against DM type 2. 
In addition, Ganoderma lucidum PsP also has potential as an 
external antioxidant agent. It could acts as scavenger against 
free-radical molecules so that it bound to antioxidants and 
unable to react with increased concentration of PUFA 
particularly on the condition of type 2 DM.(12) Reduction 
of fat deposition is causing depletion of PUFA which is 
vulnerable to oxidative process by free radicals so the 
reaction of lipid peroxidation does not occur and vascular 
damage can be avoided. 
 The antioxidant effects of Ganoderma lucidum PsP 
can be observed from the pattern of decline in the number 
of foam cell in each treatment group that received the 
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HFD-PsP as compared to the mean amount of foam cell in 
positive control group. This is due to the presence of anti-
hyperglycemia effects of Ganoderma lucidum PsP which led 
to a change of the composition of LDL cholesterol and HDL 
as well as deposition of body fat and weight loss in animals 
that received HFD and also PsP. Ganoderma lucidum PsP 
has the ability to cause a decrease in serum insulin levels, 
fasting blood glucose (GDP), and LDL cholesterol as well 
as improving HDL cholesterol in the rats who experience 
type 2 DM through the injection of STZ.(11) The decrease 
in fat deposition in the administration of Ganoderma 
lucidum PsP shows its ability as a free radical scavenger 
against increased oxidative stress conditions in type 2 DM. 
Ganoderma lucidum PsP is unable to hinder the process 
of the lipid peroxidation in rats (Rattus norvegicus) strain 
Wistar which received the HFD continuously, so that inhibit 
the onset of lipid metabolism disorders that further cause 
the oxidation of LDL cholesterol to be Ox-LDL form. Ox-
LDL levels which are reduced in the body will prevent the 
formation of foam cell through the reduction of activation 
of various pro-inflammatory cytokines, including necrosis 
factor kappa-B (NF-κB) activation so that endothelial 
dysfunction can be reduced.(16) 
 Some previous external research has proved the 
potential of Ganoderma lucidum PsP as anti-inflammatory 
agents and antioxidants. According to the Song, et al., 
Ganoderma lucidum PsP has the ability to stimulate the body's 
immune response and have the effect of anti-angiogenesis 
and anti-tumor if given in pathologic conditions.(17) 
Research by Chen, et al., and Jia, et al., also support the 
statement that Ganoderma lucidum PsP lipid peroxidation 
and blood glucose levels in diabetic model rats.(10,18) Other 
studies by Menget, et al., states that Ganoderma lucidum 
PsP has the potential in the treatment of myocardial fibrosis 
with lower accumulation of collagen levels through the 
decrease of total hydroxyproline on the myocardium of the 
ventricles of the rat heart.(19) In addition, it also obtained 
that the medium dose of Ganoderma lucidum PsP in animals 
with type 2 DM causes a decrease of glycosylation end 
product or the increased level of advanced glycosylation 
end products (AGE) in the condition of hyperglycemia and 
to prevent the process of myocardial fibrosis. Blood glucose 
and HbA1c levels in rats that received doses of Ganoderma 
lucidum PsP are also showing a significant decrease as a 
result of the administration of Ganoderma lucidum PsP. 
The results of such research in line with the hypothesis 
concerning the effects of Ganoderma lucidum PsP as 
antioxidants in this research and undertaking to strengthen 
the fact that Ganoderma  lucidum  PsP  can  be  included  in 
the  process of  atherosclerosis  preventive  efforts  in  type 
2 DM condition.(19)
 The effectiveness of PsP as an external antioxidant 
can be obtained by comparing the antioxidant abilities of 
Ganoderma lucidum PsP with another antioxidant agent. 
In comparison with ascorbic acid (Vitamin C), Ganoderma 
lucidum PsP is still 100 times less potent.(12) A study carried 
out by Fikriah about turmeric or curcumin's potential as 
antioxidants in inhibiting the development of atherosclerosis 
process claimed that turmeric was able to reduce the 
amount of foam cells with the ability which is almost 
similar to Ganoderma lucidum PsP.(20) The smaller mean 
amount of foam cells in turmeric extracts  administration 
compared to the mean amount of foam cells that arise 
after the administration of Ganoderma lucidum PsP can 
occur due to the administration of HFD or atherogenic diet 
provided in conjunction with the administration of turmeric 
extracts in a bit shorter time (10 weeks) compared with the 
administration of HFD in conjunction with Ganoderma 
lucidum PsP (12 weeks). Another benefit of the anti-
inflammatory effect of Ganoderma lucidum PsP has been 
attempted to be researched earlier. Ganoderma lucidum PsP 
has the ability to decrease the inflammatory process in type 
2 DM by inhibiting atherosclerosis process that occurs in 
rats which being induced with  STZ to stimulate type 2 DM. 
Other studies by Sliva also support the potential of 
Ganoderma lucidum as anti-inflammatory agents found that 
Ganoderma lucidum PsP actively inhibit the transcription 
factor NF-κB and activator protein-1 (AP-1) activation 
which inhibits the expression of urokinase type plasminogen 
activator-(uPA) and its receptor, uPAR.(21) The adhesion 
and migration of cells that play a role in the onset of breast 
and prostate cancer which are invasive also successfully 
repressed by Ganoderma lucidum PsP who supported 
the conclusion that Ganoderma lucidum PsP can actively 
inhibit various inflammatory processes that occur in various 
pathological conditions experienced by the body.
 Improvement of total cholesterol, triglycerides, and 
LDL cholesterol level in the groups that received PsP 
therapy are likely due to the action of PsP in regulating 
DM so that diabetic model rats is no longer experiencing 
further progress towards complications. Complications of 
DM in this study are emphasized in cardiovascular disease 
that is often caused by the presence of atherosclerosis. An 
early sign of the onset of complications of atherosclerosis 
in DM patient is the existence of dyslipidemia. Lipid profile 
improvement means the presence of dyslipidemia is reduced, 
so it can be said that the PsP can prevent cardiovascular 
complications of DM.
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Conclusion
Based on this study, the PsP can be used as adjuvant 
therapy in the management of type 2 DM, i.e., as an 
antioxidant and anti-inflammatory which can inhibit and 
slow down the process of atherosclerosis and endothelial 
damage, to eventually be able to prevent the development 
of cardiovascular complications. The administration of PsP 
can reduce the amount of foam cell and improve the lipid 
profile in diabetic model rats which are fed a diet high in fat. 
Utilization of fungus Ganoderma lucidum as a product that 
can be given easily in people with type 2 DM in order to 
bring benefit to primary and secondary prevention in tyoe 2 
DM. Further research is required to find out the effectiveness 
and safety of Ganoderma lucidum PsP, both in products that 
can be consumed (food and beverages) as well as drugs.
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